Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire To Launch Potential Dry Eye Blockbuster After FDA Backs Xiidra

Executive Summary

Securing FDA approval for its novel dry eye treatment Xiidra (lifitegrast) gives Shire PLC a potential blockbuster and key future growth driver whose indication and label are more comprehensive than that of its closest approved rival.

You may also be interested in...



Shire's Ornskov On Goals And Accomplishments One Year After Baxalta Merger

Shire's CEO says he sees scientific and technological advances as an opportunity to become the leading rare disease company. Ornskov also talked about the firm's debt-reduction and M&A strategy going forward.

3Q Pharma Results Preview: Pfizer, Gilead, Allergan, Valeant, AstraZeneca

Pfizer, Gilead, Allergan, Valeant and AstraZeneca are among the pharma and biotech companies still to report their third-quarter results. After Merck, Bristol-Myers, Lilly, Amgen, Novartis, Sanofi and others revealed their July-to-September performance, Scrip takes a look at what to expect in the weeks ahead.

GtreeBNT Aims To Validate Business Model Via Licensing Deals

2017 may be a milestone year for GtreeBNT as it progresses its late clinical stage pipeline in the US for various high-need indications including glioblastoma, the South Korean bioventure’s CEO assuring investors that he expects to see “good results” in the near future as it seeks licensing deals for its assets.

Related Content

Topics

UsernamePublicRestriction

Register

SC143162

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel